Skip to main content

BioMarin Pharmaceutical Value Stock - Dividend - Research Selection

BioMarin Pharmaceutical

ISIN: US09061G1013, WKN: 924801

Market price date: 15.08.2022
Market price: 96,94 USD

BioMarin Pharmaceutical Fundamental data and company key figures of the share

Annual reports in USD
Key figures 09-03-2022
Cash flow
Net operating cash flow 304.536.000
Capital Expenditures -95.578.000
Free cash flow 208.958.000
Balance sheet
Total Equity 4.270.740.000
Liabilities & Shareholders equity 6.003.320.000
Income statement
Net income -64.080.000
Eps (diluted) -0,350
Diluted shares outstanding 183.214.000
Net sales/revenue 1.846.270.000

Fundamental ratios calculated on: 15-08-2022

Key figures 15-08-2022
Cash flow
P/C 57,20
P/FC 85,00
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization17.418.153.984,00 USD
CountryUnited States
IndicesMSCI World Index,NASDAQ Comp.
Raw Data SourceUS GAAP in Millionen USD
Stock Split

Description of the company

BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company's product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). It is conducting clinical trials on several product candidates for the treatment of various diseases. They include Vimizim (formerly referred to as GALNS), an enzyme replacement therapy for the treatment of Mucopolysaccharidosis Type IV or Morquio Syndrome Type A (MPS IV A), PEG-PAL, an enzyme substitution therapy for the treatment of phenylketonuria (PKU), and BMN-701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder. On January 7, 2013, the Company acquired Zacharon Pharmaceuticals.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

Roche (RHHBY) Influenza Drug Gets FDA Nod for Children

Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.

Here’s Why ClearBridge Investments Sold its Position in BioMarin (BMRN)

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second quarter 2022 investor letter. A copy of the same can be downloaded here. The second quarter was difficult for growth funds, and the fund underperformed the benchmark index. Only the consumer staples sector contributed positively to the fund’s performance. To know […]

BIOMARIN PHARMACEUTICAL INC Management's Discussion and Analysis of Financial Condition and Resultsof Operations (form 10-Q)

The following discussion of our financial condition and results of operationsshould be read in conjunction with our Condensed Consolidated FinancialStatements and the related Notes thereto included... | August 4, 2022

BioMarin Lifts Annual Guidance On Better Than Expected Q2 Earnings

BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Q2 sales reached $533.8 million, up 6% Y/Y, beating the consensus of $521.47 million. BioMarin said the increase was achieved "despite continued erosion of the U.S. Kuvan market." Total revenues grew 13% Y/Y, excluding Kuvan. The company reported EPS of $0.15 compared to $0.07 a year ago, beating the consensus of $0.11. Voxzogo for achondroplasia (dwarfism) reported sales of $34.4 million. An estimated 446 children were being treated with commercial V

BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales

Biomarin Pharmaceutical's (BMRN) second-quarter earnings and sales beat estimates. BMRN slightly raises its sales guidance for the year.

BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q2 2022 Results - Earnings Call Transcript

BioMarin Pharmaceutical Inc. (NASDAQ:NASDAQ:BMRN) Q2 2022 Earnings Conference Call August 3, 2022 16:30 ET Company Participants Traci McCarty - Vice President of Investor Relations J.J.

BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BioMarin Announces Record Revenues in Second Quarter 2022; Increases Full-year 2022 Top and Bottom-line Guidance

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (BioMarin or the Company) today announced financial results for the second quarter ended June 30, 2022.

BioMarin: Q2 Earnings Snapshot

SAN RAFAEL, Calif. _ BioMarin Pharmaceutical Inc. on Wednesday reported second-quarter earnings of $27.7 million. On a per-share basis, the San Rafael, California-based company... | August 3, 2022